CL2025003893A1 - Monoclonal antibody that binds to at least 3 types of amyloid fibrils - Google Patents

Monoclonal antibody that binds to at least 3 types of amyloid fibrils

Info

Publication number
CL2025003893A1
CL2025003893A1 CL2025003893A CL2025003893A CL2025003893A1 CL 2025003893 A1 CL2025003893 A1 CL 2025003893A1 CL 2025003893 A CL2025003893 A CL 2025003893A CL 2025003893 A CL2025003893 A CL 2025003893A CL 2025003893 A1 CL2025003893 A1 CL 2025003893A1
Authority
CL
Chile
Prior art keywords
monoclonal antibody
binds
types
amyloid fibrils
amyloid
Prior art date
Application number
CL2025003893A
Other languages
Spanish (es)
Inventor
Brian Pepys Mark
Langley David
Jackson Jennifer
William Wade Jack
Christ Daniel
Henry Jake
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of CL2025003893A1 publication Critical patent/CL2025003893A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a un anticuerpo monoclonal aislado o porción de unión a antígeno de este que se une específicamente a las fibrillas amiloides y promueve eficazmente la eliminación de los depósitos amiloides extracelulares de los tejidos in vivo, así como anticuerpos humanizados que tienen las mismas propiedades.The invention relates to an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to amyloid fibrils and effectively promotes the removal of extracellular amyloid deposits from tissues in vivo, as well as humanized antibodies having the same properties.

CL2025003893A 2023-06-14 2025-12-11 Monoclonal antibody that binds to at least 3 types of amyloid fibrils CL2025003893A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies

Publications (1)

Publication Number Publication Date
CL2025003893A1 true CL2025003893A1 (en) 2026-01-30

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003893A CL2025003893A1 (en) 2023-06-14 2025-12-11 Monoclonal antibody that binds to at least 3 types of amyloid fibrils

Country Status (8)

Country Link
EP (1) EP4727650A1 (en)
KR (1) KR20260026033A (en)
CN (1) CN121487964A (en)
AU (1) AU2024304161A1 (en)
CL (1) CL2025003893A1 (en)
IL (1) IL325202A (en)
MX (1) MX2025014924A (en)
WO (1) WO2024256583A1 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69133557D1 (en) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv HOMOLOGOUS RECOMBINATION IN MAMMALIAN CELLS
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ATE549918T1 (en) 1996-12-03 2012-04-15 Amgen Fremont Inc HUMAN ANTIBODIES THAT EXPRESSLY BIND HUMAN TNF ALPHA
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
WO2015092077A1 (en) * 2013-12-20 2015-06-25 Neurimmune Holding Ag Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
CN106574258B (en) * 2014-01-29 2021-03-30 Km生物医药股份公司 Anti-Transthyretin Humanized Antibody
CN111315213B (en) * 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 anti-transthyretin antibodies
EP4237005A4 (en) * 2020-10-28 2024-10-09 Novo Nordisk A/S ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
EP4727650A1 (en) 2026-04-22
KR20260026033A (en) 2026-02-25
MX2025014924A (en) 2026-02-03
CN121487964A (en) 2026-02-06
IL325202A (en) 2026-02-01
AU2024304161A1 (en) 2025-12-11
WO2024256583A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
DOP2021000264A (en) CD3 ANTIGEN-BINDING FRAGMENTS AND COMPOSITIONS COMPRISING THE SAME
CO2019012143A2 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with antibodies against programmed death receptor 1 (pd-1) and methods for their use
EP1425042A4 (en) INHIBITOR OF COMPLEMENTARY PATH FIXING AT C5 AND C5A WITHOUT PREVENTING C5B FORMATION
CL2022002670A1 (en) Antibodies against amyloid-b with pyroglutamate and their uses (divisional application 202102473).
SA523440043B1 (en) New anti-CD3 epsilon antibodies
EA202192260A1 (en) CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND THEIR APPLICATIONS
BR112021008060A2 (en) Polypeptide, anti-ctla4 antibody or antibody fragment, immunoconjugate, pharmaceutical composition, single dose of pharmaceutical composition, method of treating cancer, and, kit for diagnosis or treatment
NO20082483L (en) Use of complement pathway inhibitors for the treatment of ocular diseases
EA202191185A1 (en) METHODS FOR INHIBITING ANGIOGENESIS IN A PATIENT
CY1120665T1 (en) HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES OF THEM AND THEIR USES
JP2013231045A5 (en)
PE20081264A1 (en) ANTI-NOTCH3 AGONIST ANTIBODIES
EA201290525A1 (en) NEW ANTIBODIES ANTAGONISTS, THEIR FAB FRAGMENTS AGAINST GPVI AND METHODS OF THEIR APPLICATION
ES2617920T3 (en) Methods for the treatment of disseminated intravascular coagulation by inhibiting the activation of MASP-2-dependent complement
PE20020574A1 (en) HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
ECSP099656A (en) ANTIBODIES OX40 ANTAGONISTS AND ITS USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
GEAP202215170A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MX2022003911A (en) ANTIBODY, PHARMACEUTICAL COMPOSITION AND METHOD.
AR069130A1 (en) LINK MOLECULES OF THE MAIN COMPLEMENT OPSONIN (C3B) AND METHODS TO MODULATE THE COMPLEMENT COMPONENT
AR108717A1 (en) ANTI-BODY COAGULATION ANTIBODIES XI
PH12021550244A1 (en) Anti-btla antibody
MX2023002496A (en) ANTIBODY THAT BINDS VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) AND ANGIOPOIETIN 2 (ANG2) AND METHODS OF USE.
AR128031A1 (en) ANTI-LTBR AGONIST ANTIBODIES AND BISPECIFIC ANTIBODIES THAT COMPRISE THEM
MX2022005949A (en) Anti-ror-2 antibodies and methods of use.
CL2023003047A1 (en) Anti-complement component 1s (c1s) antibody